Show simple item record

Pharmacodynamics of intravenous procainamide as used during acute electropharmacologic testing

dc.contributor.authorMorady, Freden_US
dc.contributor.authorKou, William H.en_US
dc.contributor.authorSchmaltz, Stephen P.en_US
dc.contributor.authorAnnesley, Thomas M.en_US
dc.contributor.authorDe Buitleir, Michaelen_US
dc.contributor.authorNelson, Steven D.en_US
dc.contributor.authorKushner, Jeffrey A.en_US
dc.date.accessioned2006-04-07T20:28:10Z
dc.date.available2006-04-07T20:28:10Z
dc.date.issued1988-01-01en_US
dc.identifier.citationMorady, Fred, Kou, William H., Schmaltz, Stephen, Annesley, Thomas, De Buitleir, Michael, Nelson, Steven D., Kushner, Jeffrey A. (1988/01/01)."Pharmacodynamics of intravenous procainamide as used during acute electropharmacologic testing." The American Journal of Cardiology 61(1): 93-98. <http://hdl.handle.net/2027.42/27475>en_US
dc.identifier.urihttp://www.sciencedirect.com/science/article/B6T10-4C76CDW-SV/2/0b2080dc613190649604670b088e6a91en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/27475
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3337024&dopt=citationen_US
dc.description.abstractNo previous studies have determined the pharmacodynamics of intravenous procainamide when administered in a dose of 15 mg/kg and at a rate of 50 mg/min, as is common practice during etectropharmacologic testing. In this study, 30 patients received procainamide in this fashion; the right ventricular effective refractory period and the QRS duration at a ventricular pacing rate of 120/minute were then determined every minute for 20 minutes. Ten patients received no maintenance infusion of procainamide (group A), 10 received a 4 [mu]g/min maintenance infusion (group B) and 10 received an 8 mg/min maintenance infusion (group C). Ten additional patients received no procainamide and served as control subjects (group D). The plasma procainamide concentration was measured at 1, 5, 10,15 and 20 minutes after the loading dose was administered. A stable plasma procainamide concentration was not present in group A, B, or C until 15 minutes after infusion of the loading dose. The effective refractory period and QRS duration increased compared with baseline at 1 minute, decreased between 1 and 10 minutes and then remained essentially unchanged between 10 and 20 minutes in all 3 treatment groups. Concentration-effect relation was linear in each treatment group. The plasma procainamide concentrations in group C were significantly greater than in group A; however, the effects on refractoriness and QRS duration were similar in both groups. These findings indicate that with a procainamide dosing method commonly used during electropharmacologic testing, the plasma procainamide concentration decreases significantly during the first 15 minutes after the loading dose is administered; the effects of procainamide on ventricular refractoriness and conduction parallel the changes in the plasma procainamide concentration; and an 8 mg/min maintenance infusion of procainamide results in higher plasma procainamide concentrations without an associated increase in ventricular refractoriness or slowing of conduction.en_US
dc.format.extent713152 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherElsevieren_US
dc.titlePharmacodynamics of intravenous procainamide as used during acute electropharmacologic testingen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Cardiology, the Clinical Research Center and the Departments of Internal Medicine and Pathology, University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDivision of Cardiology, the Clinical Research Center and the Departments of Internal Medicine and Pathology, University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDivision of Cardiology, the Clinical Research Center and the Departments of Internal Medicine and Pathology, University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDivision of Cardiology, the Clinical Research Center and the Departments of Internal Medicine and Pathology, University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationotherno department founden_US
dc.contributor.affiliationotherno department founden_US
dc.contributor.affiliationotherno department founden_US
dc.identifier.pmid3337024en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/27475/1/0000517.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1016/0002-9149(88)91311-2en_US
dc.identifier.sourceThe American Journal of Cardiologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.